Kohzo Nagata

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7223831/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mineralocorticoid Receptor Antagonism Ameliorates Left Ventricular Diastolic Dysfunction and Myocardial Fibrosis in Mildly Symptomatic Patients With Idiopathic Dilated Cardiomyopathy. Circulation, 2005, 112, 2940-2945.	1.6	236
2	Mineralocorticoid Receptor Antagonism Attenuates Cardiac Hypertrophy and Failure in Low-Aldosterone Hypertensive Rats. Hypertension, 2006, 47, 656-664.	2.7	207
3	Attenuation of cardiac dysfunction by a PPAR-α agonist is associated with down-regulation of redox-regulated transcription factors. Journal of Molecular and Cellular Cardiology, 2006, 41, 318-329.	1.9	106
4	AT 1 Receptor Blockade Reduces Cardiac Calcineurin Activity in Hypertensive Rats. Hypertension, 2002, 40, 168-174.	2.7	104
5	Elastolytic Cathepsin Induction/Activation System Exists in Myocardium and Is Upregulated in Hypertensive Heart Failure. Hypertension, 2006, 48, 979-987.	2.7	87
6	Reduced Myocardial Sarcoplasmic Reticulum Ca ²⁺ -ATPase mRNA Expression and Biphasic Force-Frequency Relations in Patients With Hypertrophic Cardiomyopathy. Circulation, 2001, 104, 658-663.	1.6	84
7	Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovascular Research, 2006, 69, 726-735.	3.8	75
8	Exercise Training Alters Left Ventricular Geometry and Attenuates Heart Failure in Dahl Salt-Sensitive Hypertensive Rats. Hypertension, 2009, 53, 701-707.	2.7	72
9	Calorie Restriction Attenuates Cardiac Remodeling and Diastolic Dysfunction in a Rat Model of Metabolic Syndrome. Hypertension, 2013, 62, 957-965.	2.7	66
10	Myocardial velocity gradient as a noninvasively determined index of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Journal of the American College of Cardiology, 2003, 42, 278-285.	2.8	62
11	Effects of various types of anesthesia on hemodynamics, cardiac function, and glucose and lipid metabolism in rats. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1360-H1366.	3.2	57
12	Cardiac remodeling and diastolic dysfunction in DahlS.Z-Leprfa/Leprfa rats: a new animal model of metabolic syndrome. Hypertension Research, 2012, 35, 186-193.	2.7	56
13	Superoxide-Dependent Cathepsin Activation Is Associated with Hypertensive Myocardial Remodeling and Represents a Target for Angiotensin II Type 1 Receptor Blocker Treatment. American Journal of Pathology, 2008, 173, 358-369.	3.8	55
14	Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: role of activation of AMP-activated protein kinase and inhibition of Akt. Journal of Hypertension, 2008, 26, 1669-1676.	0.5	53
15	Nicorandil inhibits oxidative stress-induced apoptosis in cardiac myocytes through activation of mitochondrial ATP-sensitive potassium channels and a nitrate-like effect. Journal of Molecular and Cellular Cardiology, 2003, 35, 1505-1512.	1.9	52
16	Pitavastatin Improves Cardiac Function and Survival in Association With Suppression of the Myocardial Endothelin System in a Rat Model of Hypertensive Heart Failure. Journal of Cardiovascular Pharmacology, 2006, 47, 770-779.	1.9	48
17	Nicorandil Promotes Myocardial Capillary and Arteriolar Growth in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats. Hypertension, 2005, 46, 719-724.	2.7	46
18	Effects of pioglitazone on cardiac and adipose tissue pathology in rats with metabolic syndrome. International Journal of Cardiology, 2015, 179, 360-369.	1.7	39

Κοήζο Νάςατα

#	Article	IF	CITATIONS
19	Anti-inflammatory effects of heat-killed Lactobacillus plantarum L-137 on cardiac and adipose tissue in rats with metabolic syndrome. Scientific Reports, 2018, 8, 8156.	3.3	38
20	Dietary Salt Restriction Improves Cardiac and Adipose Tissue Pathology Independently of Obesity in a Rat Model of Metabolic Syndrome. Journal of the American Heart Association, 2014, 3, e001312.	3.7	36
21	Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. International Journal of Cardiology, 2017, 240, 332-338.	1.7	36
22	Differential effects of dobutamine and a phosphodiesterase inhibitor on early diastolic filling in patients with congestive heart failure. Journal of the American College of Cardiology, 1995, 25, 295-304.	2.8	35
23	Long-term administration of nifedipine attenuates cardiac remodeling and diastolic heart failure in hypertensive rats. European Journal of Pharmacology, 2009, 615, 163-170.	3.5	34
24	Aldosterone modulates If current through gene expression in cultured neonatal rat ventricular myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2710-H2718.	3.2	32
25	Angiotensin-Converting Enzyme Inhibition Promotes Coronary Angiogenesis in the Failing Heart of Dahl Salt-Sensitive Hypertensive Rats. Journal of Cardiac Failure, 2011, 17, 1041-1050.	1.7	32
26	Effects of Estrogen on Cardiovascular Injury in Ovariectomized Female DahlS.Z- <i> Lepr ^{fa} /Lepr ^{fa} </i> Rats as a New Animal Model of Metabolic Syndrome. Hypertension, 2012, 59, 694-704.	2.7	32
27	Restraint stress exacerbates cardiac and adipose tissue pathology via β-adrenergic signaling in rats with metabolic syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1275-H1286.	3.2	32
28	ATTENUATION OF VENTRICULAR HYPERTROPHY AND FIBROSIS IN RATS BY PITAVASTATIN: POTENTIAL ROLE OF THE RhoA?EXTRACELLULAR SIGNAL-REGULATED KINASE?SERUM RESPONSE FACTOR SIGNALLING PATHWAY. Clinical and Experimental Pharmacology and Physiology, 2006, 33, 1164-1171.	1.9	30
29	Xanthine Oxidase Inhibition Improves Left Ventricular Dysfunction in Dilated Cardiomyopathic Hamsters. Journal of Cardiac Failure, 2008, 14, 238-244.	1.7	29
30	Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome. Hypertension Research, 2015, 38, 741-750.	2.7	27
31	Comparison of the effects of cilnidipine and amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Journal of Hypertension, 2012, 30, 1845-1855.	0.5	23
32	Mechanism of Diastolic Stiffening of the Failing Myocardium and Its Prevention by Angiotensin Receptor and Calcium Channel Blockers. Journal of Cardiovascular Pharmacology, 2009, 54, 47-56.	1.9	19
33	Mechanism underlying the efficacy of combination therapy with losartan and hydrochlorothiazide in rats with salt-sensitive hypertension. Hypertension Research, 2011, 34, 809-816.	2.7	19
34	Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury. Hypertension Research, 2014, 37, 125-133.	2.7	18
35	Glucocorticoid-induced hypertension and cardiac injury: effects of mineralocorticoid and glucocorticoid receptor antagonism. Nagoya Journal of Medical Science, 2013, 75, 81-92.	0.3	18
36	Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Hypertension Research, 2015, 38, 39-47.	2.7	16

Κοήζο Νάβατα

#	Article	IF	CITATIONS
37	Ca2+ channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats. Journal of Hypertension, 2010, 28, 1515-1526.	0.5	15
38	Effects of mTOR inhibition on cardiac and adipose tissue pathology and glucose metabolism in rats with metabolic syndrome. Pharmacology Research and Perspectives, 2017, 5, e00331.	2.4	14
39	Mineralocorticoid antagonism and cardiac hypertrophy. Current Hypertension Reports, 2008, 10, 216-221.	3.5	13
40	Effects of Aged Garlic Extract on Left Ventricular Diastolic Function and Fibrosis in a Rat Hypertension Model. Experimental Animals, 2013, 62, 305-310.	1.1	13
41	Generation of Rat-Induced Pluripotent Stem Cells from a New Model of Metabolic Syndrome. PLoS ONE, 2014, 9, e104462.	2.5	10
42	Glucocorticoids activate cardiac mineralocorticoid receptors in adrenalectomized Dahl salt-sensitive rats. Nagoya Journal of Medical Science, 2014, 76, 59-72.	0.3	10
43	Premature cardiac senescence in DahlS.Z-Lepr(fa)/Lepr(fa) rats as a new animal model of metabolic syndrome. Nagoya Journal of Medical Science, 2014, 76, 35-49.	0.3	10
44	Effects of ramelteon on cardiac injury and adipose tissue pathology in rats with metabolic syndrome. Annals of the New York Academy of Sciences, 2018, 1421, 73-87.	3.8	9
45	Lamininα2-secreting fibroblasts enhance the therapeutic effect of skeletal myoblast sheets. European Journal of Cardio-thoracic Surgery, 2016, 51, ezw296.	1.4	7
46	Roles of oxidative stress and the mineralocorticoid receptor in cardiac pathology in a rat model of metabolic syndrome. Nagoya Journal of Medical Science, 2015, 77, 275-89.	0.3	6
47	The prebiotic fiber inulin ameliorates cardiac, adipose tissue, and hepatic pathology, but exacerbates hypertriglyceridemia in rats with metabolic syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 320, H281-H295.	3.2	5
48	Alleviation of salt-induced exacerbation of cardiac, renal, and visceral fat pathology in rats with metabolic syndrome by surgical removal of subcutaneous fat. Nutrition and Diabetes, 2020, 10, 28.	3.2	4
49	Cardioprotective mechanisms of lifestyle modifications and pharmacotherapies on cardiac remodeling and dysfunction in hypertensive heart disease: an overview. Nagoya Journal of Medical Science, 2011, 73, 91-105.	0.3	4
50	Pharmacological inhibition of the lipid phosphatase PTEN ameliorates heart damage and adipose tissue inflammation in stressed rats with metabolic syndrome. Physiological Reports, 2022, 10, e15165.	1.7	2
51	Effects of FK506 and rapamycin on formation of the neural tube in chick embryos. Animal Science Journal, 2002, 73, 229-234.	1.4	1
52	Surgical ablation of whitened interscapular brown fat ameliorates cardiac pathology in saltâ€loaded metabolic syndrome rats. Annals of the New York Academy of Sciences, 2021, 1492, 11-26.	3.8	1